University of Pristina, Kosovo; University Clinical Center of Kosovo, Kosovo.
Biomed Pharmacother. 2022 Sep;153:113368. doi: 10.1016/j.biopha.2022.113368. Epub 2022 Jun 30.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the outbreak of unusual viral pneumonia that emerged in late 2019 in the city of Wuhan, China. Since then, because of its high transmission and pathogenic potential it spread almost all over the world causing the pandemic, as an extraordinary threat to the world public health. Rapid activation of a well-orchestrated and functional immune system with its both arms innate and adaptive immune response is pivotal to eradication of the disease caused by this coronavirus (COVID-19). Therefore, in this review are summarized the most recent data on complex molecular mechanisms involved in the innate and adaptive immune response to combat COVID-19. In addition to widely used vaccines against SARS-CoV-2, because of the induction of short-lived immunity and appearance of variants of concern (VOCs), there will be also discussed newly developed strategies to target different viral proteins, which are not prone to frequent mutations. Obviously, SARS-CoV-2 cannot evade the effect of these novel drugs and therefore they show a great promise as an antiviral therapy not only in COVID-19 but also in future viral outbreaks.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引发了 2019 年末在中国武汉市出现的异常病毒性肺炎疫情。此后,由于其高传播性和致病潜力,它几乎蔓延到世界各地,引发了大流行,对全球公共卫生构成了特殊威胁。迅速激活协调良好且功能强大的免疫系统,包括先天免疫和适应性免疫反应,是消除这种冠状病毒(COVID-19)引起的疾病的关键。因此,本文总结了最近关于先天免疫和适应性免疫反应对抗 COVID-19 的复杂分子机制的研究数据。除了广泛使用的 SARS-CoV-2 疫苗外,由于诱导的短暂免疫和出现关注变异株(VOCs),本文还将讨论针对不易频繁突变的不同病毒蛋白的新开发策略。显然,SARS-CoV-2 无法逃避这些新型药物的作用,因此它们作为抗病毒疗法在 COVID-19 以及未来的病毒爆发中具有广阔的应用前景。